Literature DB >> 24980194

A recipe for targeted therapy in prostate cancer.

Shigeo Masuda1, Juan Carlos Izpisua Belmonte1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24980194     DOI： 10.1038/nrurol.2013.110-c1

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  12 in total

1.  Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells.

Authors:  Johan H van Es; Marielle E van Gijn; Orbicia Riccio; Maaike van den Born; Marc Vooijs; Harry Begthel; Miranda Cozijnsen; Sylvie Robine; Doug J Winton; Freddy Radtke; Hans Clevers
Journal:  Nature       Date:  2005-06-16       Impact factor: 49.962

Review 2.  Hypoxia, notch signalling, and prostate cancer.

Authors:  Laure Marignol; Karla Rivera-Figueroa; Thomas Lynch; Donal Hollywood
Journal:  Nat Rev Urol       Date:  2013-05-28       Impact factor: 14.432

3.  Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia.

Authors:  Max Jan; Thomas M Snyder; M Ryan Corces-Zimmerman; Paresh Vyas; Irving L Weissman; Stephen R Quake; Ravindra Majeti
Journal:  Sci Transl Med       Date:  2012-08-29       Impact factor: 17.956

4.  Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis.

Authors:  John Ridgway; Gu Zhang; Yan Wu; Scott Stawicki; Wei-Ching Liang; Yvan Chanthery; Joe Kowalski; Ryan J Watts; Christopher Callahan; Ian Kasman; Mallika Singh; May Chien; Christine Tan; Jo-Anne S Hongo; Fred de Sauvage; Greg Plowman; Minhong Yan
Journal:  Nature       Date:  2006-12-21       Impact factor: 49.962

5.  Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

Authors:  William Kevin Kelly; Susan Halabi; Michael Carducci; Daniel George; John F Mahoney; Walter M Stadler; Michael Morris; Philip Kantoff; J Paul Monk; Ellen Kaplan; Nicholas J Vogelzang; Eric J Small
Journal:  J Clin Oncol       Date:  2012-03-26       Impact factor: 44.544

6.  Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.

Authors:  Ian F Tannock; Karim Fizazi; Sergey Ivanov; Camilla Thellenberg Karlsson; Aude Fléchon; Iwona Skoneczna; Francisco Orlandi; Gwenaelle Gravis; Vsevolod Matveev; Sevil Bavbek; Thierry Gil; Luciano Viana; Osvaldo Arén; Oleg Karyakin; Tony Elliott; Alison Birtle; Emmanuelle Magherini; Laurence Hatteville; Daniel Petrylak; Bertrand Tombal; Mark Rosenthal
Journal:  Lancet Oncol       Date:  2013-06-04       Impact factor: 41.316

7.  Dual antitumor mechanisms of Notch signaling inhibitor in a T-cell acute lymphoblastic leukemia xenograft model.

Authors:  Shigeo Masuda; Keiki Kumano; Takahiro Suzuki; Taisuke Tomita; Takeshi Iwatsubo; Hideaki Natsugari; Arinobu Tojo; Makoto Shibutani; Kunitoshi Mitsumori; Yutaka Hanazono; Seishi Ogawa; Mineo Kurokawa; Shigeru Chiba
Journal:  Cancer Sci       Date:  2009-08-27       Impact factor: 6.716

Review 8.  The Notch pathway in prostate development and cancer.

Authors:  Kevin G Leong; Wei-Qiang Gao
Journal:  Differentiation       Date:  2008-06-28       Impact factor: 3.880

9.  Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties.

Authors:  Leopoldo Luistro; Wei He; Melissa Smith; Kathryn Packman; Maria Vilenchik; Daisy Carvajal; John Roberts; James Cai; Windy Berkofsky-Fessler; Holly Hilton; Michael Linn; Alexander Flohr; Roland Jakob-Røtne; Helmut Jacobsen; Kelli Glenn; David Heimbrook; John F Boylan
Journal:  Cancer Res       Date:  2009-09-22       Impact factor: 12.701

10.  Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia.

Authors:  Pedro J Real; Valeria Tosello; Teresa Palomero; Mireia Castillo; Eva Hernando; Elisa de Stanchina; Maria Luisa Sulis; Kelly Barnes; Catherine Sawai; Irene Homminga; Jules Meijerink; Iannis Aifantis; Giuseppe Basso; Carlos Cordon-Cardo; Walden Ai; Adolfo Ferrando
Journal:  Nat Med       Date:  2008-12-21       Impact factor: 53.440
View more
  2 in total

1.  Targeting notch in prostate cancer--combination is the key.

Authors:  Laure Marignol
Journal:  Nat Rev Urol       Date:  2014-07-01       Impact factor: 14.432

Review 2.  Notch signaling in the prostate: critical roles during development and in the hallmarks of prostate cancer biology.

Authors:  Gang Deng; Libin Ma; Qi Meng; Xiang Ju; Kang Jiang; Peiwu Jiang; Zhijian Yu
Journal:  J Cancer Res Clin Oncol       Date:  2015-03-04       Impact factor: 4.553
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.